Items where authors include "Morgan, G.J."

Article

Giles, H.V., Drayson, M.T., Kishore, B. et al. (11 more authors) (2024) Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry. Blood Cancer Journal, 14. 50. ISSN 2044-5385

Jones, J.R., Cairns, D.A. orcid.org/0000-0002-2338-0179, Menzies, T. et al. (14 more authors) (2023) Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. eClinicalMedicine, 62. 102099. ISSN 2589-5370

Jenner, M.W., Pawlyn, C., Davies, F.E. et al. (15 more authors) (2023) The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial. British Journal of Haematology, 201 (2). pp. 267-279. ISSN 0007-1048

Jackson, G.H., Pawlyn, C., Cairns, D.A. et al. (20 more authors) (2021) Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLOS Medicine, 18 (1). e1003454. ISSN 1549-1277

Spink, C.F., Keen, L.J., Mensah, F.K. et al. (3 more authors) (2006) Association between non-Hodgkin lymphoma and haplotypes in the TNF region. British Journal of Haematology, 133 (3). pp. 293-300. ISSN 0007-1048

Lightfoot, T.J., Skibola, C.F., Willett, E.V. et al. (7 more authors) (2005) Risk of non-Hodgkin lymphoma associated with polymorphisms in folate-metabolizing genes. Cancer Epidemiology Biomarkers & Prevention, 14 (12). pp. 2999-3003. ISSN 1055-9965

Willett, E.V., Skibola, C.F., Adamson, P. et al. (4 more authors) (2005) Non-Hodgkin's Lymphoma: obesity and energy homeostasis polymorphisms. British Journal of Cancer, 93 (7). pp. 811-816. ISSN 0007-0920

Willett, E.V., Smith, A.G., Dovey, G.J. et al. (3 more authors) (2004) Tobacco and alcohol consumption and the risk of non-Hodgkin lymphoma. Cancer Causes and Control, 15 (8). pp. 771-780. ISSN 0957-5243

Barrans, S.L., Evans, P.A.S., O’Connor, S.J.M. et al. (5 more authors) (2003) The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clinical Cancer Research, 9 (6). pp. 2133-2139. ISSN 1078-0432

Barrans, S.L., Carter, I., Owen, R.G. et al. (5 more authors) (2002) Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood, 99 (4). pp. 1136-1143. ISSN 0006-4971

Allan, J.M., Wild, C.P., Rollinson, S. et al. (7 more authors) (2001) Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapyinduced leukemia. Proceedings of the National Academy of Sciences, 98 (20). pp. 11592-11597. ISSN 0027-8424

Allan, J.M., Wild, C.P., Rollinson, S. et al. (7 more authors) (2001) Polymorphism in glutathione S-transferase is associated with susceptibility to chemotherapy-induced leukemia. Proceedings of the National Academy of Sciences of the United States of America, 98 (98). pp. 11592-11597. ISSN 0027-8424

Proceedings Paper

Reed, M., Cairns, D.A. orcid.org/0000-0002-2338-0179, Pawlyn, C. et al. (13 more authors) (2023) The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial. In: Blood. 65th ASH Annual Meeting and Exposition, 09-12 Dec 2023, San Diego, USA. American Society of Hematology , pp. 3366-3368.

Jackson, G.H., Davies, F.E., Pawlyn, C. et al. (18 more authors) (2016) Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .

Pawlyn, C., Davies, F.E., Kaiser, M.F. et al. (18 more authors) (2016) Primary IMiD refractory myeloma; results from 3894 patients treated in the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .

Jackson, G.H., Davies, F.E., Pawlyn, C. et al. (18 more authors) (2016) Response adapted induction treatment improves outcomes for myeloma patients; results of the Phase III Myeloma XI Study. In: Blood. 58th ASH Annual Meeting, 03-06 Dec 2016, San Diego, CA, USA. American Society of Hematology .